Photo: in.investing.com
Nexalin stock soars after Alzheimer's treatment shows cognitive benefits By Investing.com
Nexalin Technology Inc's stock soared 84.4% after revealing positive clinical data indicating its neurostimulation technology enhanced cognition in patients with mild Alzheimer's disease.
- Nexalin Technology Inc (NASDAQ:NXL) experienced an 84.4% stock surge in premarket trading on Wednesday following the release of promising clinical data.
- The reported clinical trial demonstrated that Nexalin's brain stimulation technology significantly improved cognitive performance in patients diagnosed with mild Alzheimer's disease.
- Positive results were supported by functional magnetic resonance imaging data, highlighting the effectiveness of Nexalin's neurostimulation approach in enhancing cognition.
Why It Matters
This breakthrough underscores the potential of neurostimulation therapies in addressing cognitive decline associated with Alzheimer's disease, marking a significant advancement in treatment options and investor confidence in healthcare innovation.